Results 101 to 110 of about 2,437,081 (240)

Six‐Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics

Respirology Case Reports, Volume 14, Issue 2, February 2026.
We report a case of relapsing chronic eosinophilic pneumonia where benralizumab showed superior durability compared to mepolizumab. Based on the eosinophil recovery kinetics (relapse at 8 months after withdrawal), a personalised maintenance strategy of benralizumab every 6 months was established, successfully maintaining remission for over 2 years ...
Toshiyuki Sumi, Taiki Ishigooka, Kazuya Takeda, Taeka Naraoka, Naoki Shijubou, Yuichi Yamada, Hirofumi Chiba   +6 more
wiley   +1 more source

Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report. [PDF]

, 2004
A 34-year-old woman was admitted to our emergency room with a high fever, abdominal pain, dyspnea and confusion. High fever and abdominal pain had first occured after a cystocele operation 5 months earlier.
Erten, Nilgun, Karan, M Akif, Parman, Yesin, Saka, Bulent, Tascioglu, Cemil, Umman, Berrin   +5 more
core   +1 more source

Acute collapse in a dog with multiple autoimmune syndromes and polymyositis complicated by suspected organophosphate/carbamate toxicity

Veterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 6.5‐year‐old, spayed, female dog presented in acute respiratory distress. On admission, the dog exhibited dyspnoea, bradycardia, cyanosis and gastrointestinal signs, requiring immediate intubation and mechanical ventilation. Diagnostic evaluation revealed reduced butyrylcholinesterase activity, non‐cardiogenic pulmonary oedema, elevated ...
Sarah Hefer, Efrat Kelmer, Michal Mazaki Tovi, Dana Peery, Kobi Aharoni, Nir Edry, Sigal Klainbart   +6 more
wiley   +1 more source

Late-Stage Löffler's Endocarditis Mimicking Cardiac Tumor: A Case Report

Frontiers in Cardiovascular Medicine, 2020
Löffler's endocarditis (cardiac involvement in hypereosinophilic syndrome) is rare yet life-threatening if left untreated. We describe a case of hypereosinophilic syndrome presenting as a cardiac mass with an abnormal electrocardiogram.
Takafumi Koyama, Hiroyuki Yamamoto, Manabu Matsumoto, Jun Isogai, Tadashi Isomura, Shinji Tanaka   +5 more
doaj   +1 more source

Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. [PDF]

, 2020
Since 2013, the International Union of Immunological Societies (IUIS) expert committee (EC) on Inborn Errors of Immunity (IEI) has published an updated phenotypic classification of IEI, which accompanies and complements their genotypic classification ...
Ailal, Fatima, Al-Herz, Waleed, Bousfiha, Aziz, Casanova, Jean-Laurent, Chatila, Talal, Cunningham-Rundles, Charlotte, Etzioni, Amos, Franco, Jose Luis, Holland, Steven M, Jeddane, Leila, Klein, Christoph, Morio, Tomohiro, Ochs, Hans D, Oksenhendler, Eric, Picard, Capucine, Puck, Jennifer, Sullivan, Kathleen E, Tangye, Stuart G, Torgerson, Troy R   +18 more
core  

Review of published research on primary dysautonomia of domestic animals

Veterinary Record, Volume 198, Issue 1, Page e30-e40, 3/10 January 2026.
Abstract An article published in 1992 by Marion M. Pollin and I.R. Griffiths reviewed the topic of primary dysautonomias of the autonomic nervous system of unidentified origin in multiple domestic species, specifically cats, dogs and horses. Thirty‐one years later, we appear no closer to identifying the causal agents of these strikingly similar ...
Tanith Harte, David Smith, Jo Moore, Beth Wells   +3 more
wiley   +1 more source

Real‐World Treatment Patterns in AERD: An Analysis of ATAD, Biologics, and Combination Therapy

International Forum of Allergy &Rhinology, Volume 16, Issue 1, Page 99-101, January 2026.
Key Points Contemporary aspirin exacerbated respiratory disorder (AERD) therapy commonly includes aspirin desensitization (55%) and biologics (48%). Aspirin desensitization therapy has higher discontinuation rates than biologics. Patients receiving biologics are younger, and ∼25% of the patients switch to other agents.
Nitish Kumar, Tyson Pace, Pedro Lança Gomes, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Hypereosinophilic Dermatitis: Successful Treatment with Dupilumab

Biologics: Targets & Therapy, 2023
Chenyu Wu, Jianzhong Zhang, Yan Zhao Department of Dermatology, People’s Hospital of Peking University, Beijing, People’s Republic of ChinaCorrespondence: Yan Zhao, Email 13311373780@163.comAbstract: Hypereosinophilic dermatitis (HED) is a subtype of ...
Wu C, Zhang J, Zhao Y
doaj  

Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.

Journal of Allergy and Clinical Immunology: In Practice, 2018
BACKGROUND Conventional therapies for hypereosinophilic syndromes (HES) have variable efficacy and carry significant long-term toxicities. Anti-IL-5 (mepolizumab) therapy has a glucocorticoid (GC)-sparing effect in GC-sensitive HES, but the efficacy of ...
F. Kuang, M. Fay, JeanAnne M Ware, L. Wetzler, Nicole C Holland-Thomas, Thomas Brown, H. Ortega, J. Steinfeld, P. Khoury, A. Klion   +9 more
semanticscholar   +1 more source

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

British Journal of Haematology, Volume 208, Issue 1, Page 116-128, January 2026.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, Kar Lok Kong, David G. Kent, Helen Lachmann, Austin Kulasekararaj, Catherine Cargo, Sinisa Savic   +15 more
wiley   +1 more source